TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant

Inclusion Criteria: * Patients \> 18 years old * Any patients with allogenic TPH * Following in post-TPH with antigenemia or PCR-CMV * CMV in blood test detected by antigenemia or PCR before the day 180 post-TPH * The beginning of treatment must be Duch early as possible. Maximum in the 72 hours from the antigenemia or PCR-CMV detection * Be the first or second time of a CMV infection * Sign the informed consent * Pregnancy negative test in fertile age patients Exclusion Criteria: * Patients received auto or syngenic TPH * Patients \<50 kg weight * Known allergy or hypersensibility patients to valganciclovir, ganciclovir or aciclovir * Digestive intolerant: nauseous, vomit and or diarrhea that could difficult oral administration of valganciclovir * Patients that presents CMV infection or that is being evaluated for suspected CMV * Patients that have presented \>2 CMV infection episode, before the current one * Severe liver disease defined by bilirubin ≥ 10mg/dL * Treated with: foscarnet, ganciclovir, cidofovir or another antiviral drug active to CMV, in the previous 30 days at the current episode * Neutrophils \< 500 /µL at the beginning of valganciclovir treatment. Patients with \>500 PMN/µL and \< 1000/µL must start a G-CSF treatment to get neutrophils value \> 1000/µL * Platelets \< 25/mm3 even receiving transfusion * Clearance Creatinine \< 10mL/min or dialysed patients * Pregnancy or lactant women * Other contraindication detailed in the "filling card" * Previous inclusión in this study at the treated group. Is allowed that a patient participate as a control case and after that receive valganciclovir treatment in after CMV episode